FDA Commissioner Marty Makary Resigns After 13 Months Amid Policy and Leadership Turmoil

FDA Commissioner Marty Makary Steps Down After Turbulent 13-Month Tenure

Marty Makary, Commissioner of the U.S. Food and Drug Administration (FDA), is stepping down after a 13-month term characterized by significant organizational upheaval, drug approval controversies, and tensions with the White House. Kyle Diamantas, the agency’s deputy commissioner for food, will serve as acting commissioner, according to sources familiar with the matter.

Why This Matters

Under Makary’s leadership, the FDA became a focal point of controversy and a lightning rod for broader health policy disputes spearheaded by Health Secretary Robert F. Kennedy Jr. His departure leaves the Trump administration with three Senate-confirmed health positions to fill, including vacancies for the directors of the Centers for Disease Control and Prevention (CDC) and the Surgeon General.

Key Controversies and Challenges

Makary, a physician and researcher affiliated with Johns Hopkins University, faced repeated criticism during his tenure. Issues included:

• Abortion pills: Anti-abortion groups demanded Makary’s removal after he did not reinstate stricter rules for obtaining mifepristone, including in-person dispensing requirements. The FDA approved a generic version of the drug under his leadership.
• Flavored vapes: President Trump reportedly pressured Makary to approve flavored vapes after he initially resisted, according to The Wall Street Journal.
• Vaccines: The FDA became a central figure in vaccine-related disputes.
• Rare disease drugs: The agency faced backlash for rejecting certain treatments for rare diseases. Vinay Prasad, who led the biologics division and has since left the agency, was at the center of these decisions.
• Investor concerns: Health care investors criticized Makary for unpredictable regulatory decisions that rejected promising drugs.

Makary also launched initiatives to modernize the FDA’s regulatory functions, including real-time clinical trials, the awarding of vouchers to expedite reviews of priority treatments, and efforts to reduce animal testing. However, these moves did not quell the ongoing controversies.

White House Response and Trump’s Remarks

When asked on Tuesday whether he had fired Makary or requested his resignation, President Trump responded,

"Well, I don't want to say, but Marty is a great guy. ... He was having some difficulty."

"Marty's a terrific guy, but he's going to go on and he's going to lead a good life."

The Bigger Picture: Leadership Challenges and Turnover

Makary entered the role as a respected figure in the medical community but quickly encountered turmoil. His confirmation coincided with layoffs at the Department of Health and Human Services (HHS), where many health agency staff were let go. The FDA’s drug center experienced significant turnover, cycling through four different directors in a single year.

What’s Next for the FDA?

As the administration seeks to move beyond vaccine-related controversies, the appointment of Makary’s successor will signal whether the Trump administration is prioritizing policy changes. Raymond James analyst Chris Meekins noted in an investor note prior to the announcement,

"Finding someone industry welcomes and MAHA does not despise may be a bit of a challenging channel to navigate."